175 related articles for article (PubMed ID: 23517183)
21. Insights into the Protein Ruthenation Mechanism by Antimetastatic Metallodrugs: High-Resolution X-ray Structures of the Adduct Formed between Hen Egg-White Lysozyme and
Chiniadis L; Giastas P; Bratsos I; Papakyriakou A
Inorg Chem; 2021 Jul; 60(14):10729-10737. PubMed ID: 34197115
[TBL] [Abstract][Full Text] [Related]
22. Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study.
Levina A; Aitken JB; Gwee YY; Lim ZJ; Liu M; Singharay AM; Wong PF; Lay PA
Chemistry; 2013 Mar; 19(11):3609-19. PubMed ID: 23361836
[TBL] [Abstract][Full Text] [Related]
23. The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins.
Casini A; Temperini C; Gabbiani C; Supuran CT; Messori L
ChemMedChem; 2010 Dec; 5(12):1989-94. PubMed ID: 20931644
[No Abstract] [Full Text] [Related]
24. Succinimide and isoaspartate residues in the crystal structures of hen egg-white lysozyme complexed with tri-N-acetylchitotriose.
Noguchi S; Miyawaki K; Satow Y
J Mol Biol; 1998 Apr; 278(1):231-8. PubMed ID: 9571046
[TBL] [Abstract][Full Text] [Related]
25. Ru-Based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography.
Pontillo N; Ferraro G; Messori L; Tamasi G; Merlino A
Dalton Trans; 2017 Jul; 46(29):9621-9629. PubMed ID: 28702564
[TBL] [Abstract][Full Text] [Related]
26. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
[TBL] [Abstract][Full Text] [Related]
27. Structural characterization of protein-denaturant interactions: crystal structures of hen egg-white lysozyme in complex with DMSO and guanidinium chloride.
Mande SC; Sobhia ME
Protein Eng; 2000 Feb; 13(2):133-41. PubMed ID: 10708653
[TBL] [Abstract][Full Text] [Related]
28. Interaction between proteins and Ir based CO releasing molecules: mechanism of adduct formation and CO release.
Petruk AA; Vergara A; Marasco D; Bikiel D; Doctorovich F; Estrin DA; Merlino A
Inorg Chem; 2014 Oct; 53(19):10456-62. PubMed ID: 25215611
[TBL] [Abstract][Full Text] [Related]
29. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study.
Besker N; Coletti C; Marrone A; Re N
J Phys Chem B; 2008 Apr; 112(13):3871-5. PubMed ID: 18331025
[TBL] [Abstract][Full Text] [Related]
30. Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: a computational study.
Gossens C; Tavernelli I; Rothlisberger U
J Phys Chem A; 2009 Oct; 113(43):11888-97. PubMed ID: 19791792
[TBL] [Abstract][Full Text] [Related]
31. Specific derivatization of lysozyme in aqueous solution with Re(CO)3(H2O)3(+).
Binkley SL; Ziegler CJ; Herrick RS; Rowlett RS
Chem Commun (Camb); 2010 Feb; 46(8):1203-5. PubMed ID: 20449250
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
33. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
34. Half-sandwich arene ruthenium(II)-enzyme complex.
McNae IW; Fishburne K; Habtemariam A; Hunter TM; Melchart M; Wang F; Walkinshaw MD; Sadler PJ
Chem Commun (Camb); 2004 Aug; (16):1786-7. PubMed ID: 15306883
[TBL] [Abstract][Full Text] [Related]
35. DNA-binding behavior of ruthenium(II) complexes containing both group 15 donors and 2,2':6',2''-terpyridine.
Sharma S; Singh SK; Chandra M; Pandey DS
J Inorg Biochem; 2005 Feb; 99(2):458-66. PubMed ID: 15621278
[TBL] [Abstract][Full Text] [Related]
36. On the pH-Modulated Ru-Based Prodrug Activation Mechanism.
Caterino M; Herrmann M; Merlino A; Riccardi C; Montesarchio D; Mroginski MA; Musumeci D; Ruffo F; Paduano L; Hildebrandt P; Kozuch J; Vergara A
Inorg Chem; 2019 Jan; 58(2):1216-1223. PubMed ID: 30614697
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
Tan C; Hu S; Liu J; Ji L
Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
[TBL] [Abstract][Full Text] [Related]
38. Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme.
Messori L; Marzo T; Gabbiani C; Valdes AA; Quiroga AG; Merlino A
Inorg Chem; 2013 Dec; 52(24):13827-9. PubMed ID: 24256441
[TBL] [Abstract][Full Text] [Related]
39. Ruthenium-based complex nanocarriers for cancer therapy.
Mangiapia G; D'Errico G; Simeone L; Irace C; Radulescu A; Di Pascale A; Colonna A; Montesarchio D; Paduano L
Biomaterials; 2012 May; 33(14):3770-82. PubMed ID: 22357152
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.
Wu K; Luo Q; Hu W; Li X; Wang F; Xiong S; Sadler PJ
Metallomics; 2012 Feb; 4(2):139-48. PubMed ID: 22262368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
